Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Summary: Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its i...

Full description

Bibliographic Details
Main Authors: Jun-Gyu Park, Fatai S. Oladunni, Mohammed A. Rohaim, Jayde Whittingham-Dowd, James Tollitt, Matthew D.J. Hodges, Nadin Fathallah, Muhsref Bakri Assas, Wafaa Alhazmi, Abdullah Almilaibary, Munir Iqbal, Pengxiang Chang, Renee Escalona, Vinay Shivanna, Jordi B. Torrelles, John J. Worthington, Lucy H. Jackson-Jones, Luis Martinez-Sobrido, Muhammad Munir
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:iScience
Subjects:
immunology
virology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221009093

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221009093

Similar Items